Autoimmunity
A significant focus in biotech.
Autoimmune diseases include Crohn’s disease, celiac disease, lupus, multiple sclerosis, psoriasis, rheumatoid arthritis, scleroderma, Sjögren's disease and type 1 diabetes. This group of chronic conditions represents a substantial and growing area of research and therapeutic innovation.
I&A
Significant Unmet Medical Need
- Increasing disease prevalence
- Many patients are diagnosed young and require lifelong therapy
- Significant unmet needs remain
Immunology and Autoimmune (I&A) disease is a large market and unfortunately in terms of the disease burden for patients, it continues to increase.
Many common diseases have doubled in prevalence, and this phenomenon is true both in the US and globally.
Patients oftentimes present in the first half of life and typically experience chronic illness that requires some version of lifelong therapy – resulting in significant cost over the course of that patient’s life.
While there have been important advances, significant unmet medical needs remain.
A Large and Growing Market
- Pipeline-in-a-product
- Robust partnering and M&A activity
- Underinvested relative to the expected future revenue, and venture capital is noticing
In recent years, global revenue of the largest immunology products has reached approximately $150 billion, which is approximately 20% of the global pharmaceutical market.
Immunology is a growth market, and by some estimates, it will grow at double or triple the rate of the overall pharmaceutical industry.
Up to half of human disease is associated with inflammatory and immunological conditions.
Inflection Point of Innovation
- Novel technologies enabling breakthrough treatments and potential for prevention
- Insights across diseases
- The biology is being decoded
Immuno-oncology revolution offers insights and tools to address other diseases of the immune system.
Innovation can be accelerated by harvesting a deep understanding of the links between autoimmune diseases.
Opportunities to leverage biological insights, develop biomarkers, better select patients for clinical studies, and better design clinical trials across indications.
